Navigation Links
New Mechanism Identified for Resistance to Targeted Lung Cancer Drugs

An international research team, led by investigators from the Massachusetts General Hospital (MGH) Cancer Center and Dana-Farber Cancer Institute (DFCI), has found// a new way that some lung tumors become resistant to treatment with targeted therapy drugs like Iressa and Tarceva. Their report, which will appear in the journal Science and is receiving early online release, describes a totally new resistance mechanism that may apply to many types of cancer. It also suggests a treatment strategy for patients with these resistant tumors.

"We found that, for about 20 percent of patients with tumors that become resistant to Tarceva or Iressa, resistance is caused by the genetic activation of an oncogene that is not the normal target of the drug, which is something that has never been seen before," says Jeffrey Engelman, MD, PhD, scientific director of the MGH Center for Thoracic Cancers, the paper's lead author.

"Importantly, we also identified a potential new way to treat these resistant tumors with combination therapy directed against both protein targets," adds Pasi A. J?nne, MD, PhD, of the Lowe Center for Thoracic Oncology at DFCI, the study's senior author.

Drugs like Iressa (gefitinib) and Tarceva (erlotinib) are used to treat advanced non-small-cell lung cancer (NSCLC), the leading cause of cancer deaths in the U.S. They act by blocking the epidermal growth factor receptor (EGFR), a molecule on the surface of cancer cells. In 2004 research teams from MGH and DFCI found that only tumors in which the EGFR gene has been mutated in a way that magnifies the cells' response to the growth factor, a process that fuels tumor growth, were sensitive to treatment with these drugs.

Although tumors that respond to EGFR inhibitors do so rapidly and dramatically, eventually the tumors become resistant and resume growing. About half the time, a secondary mutation that interferes with the drugs' binding to the receptor develops within the EGFR gene. A new group of so-called irreversible EGFR inhibitors that permanently bind to the protein are currently being tested in clinical trials. But what leads to other cases of resistance has been unknown, and the current study was designed to discover additional mechanisms.

To do so, the investigators modeled in a laboratory setting what happens in lung cancer patients; they used a line of NSCLC cells with the sensitizing EGFR mutation and created a cell line resistant to treatment with Iressa. In a number of experiments comparing the resistant line with still-sensitive cells, they focused on the cell signalling pathway controlled by EGFR. In earlier research, Engelman and colleagues had found that the growth signal that starts with EGFR works through a related protein called ERBB3.

The current study showed that, in some of the resistant cells, ERBB3 is activated by amplification of a different oncogene called MET, in essence bypassing the blockage of EGFR. Analysis of samples from patients whose tumors became resistant after initially responding to Iressa revealed that MET was amplified in resistant samples from 4 of 18 patients. Although treating resistant cell lines with either Iressa or a MET inhibitor did not stop tumor growth, treatment with both agents did induce cell death.

"This method of reactivating the EGFR signalling pathway with MET may be a common resistance mechanism in other therapies that target receptors of the ERBB family, which are used against breast cancer, colon cancer, head and neck cancer, and the brain tumor glioblastoma multiforme," says J?nne, who is an assistant professor of Medicine at Harvard Medical School (HMS). Engelman is an HMS instructor of Medicine.

"Our results suggest that, when patients' tumors become resistant, repeat biopsies to identify which resistance mechanism is involved will be critical and could help us develop effective therapies for those resistant tumors, " adds co-author Lewis Cantley, PhD, of the Beth Israel Deaconess Medical Center.

To that end, the investigators are working on a research protocol for combined treatment with FDA-approved EGFR inhibitors and with MET inhibitors, which are in preapproval trials against other types of cancer. They also plan to analyze a larger number of resistant samples to get a clearer idea of the frequency of this resistance mechanism.

Source-Eurekalert/M
'"/>




Related medicine news :

1. Scientists Unveil Mechanism Behind Resistance to Severe Malaria
2. New Gene Silencing Mechanism To Prevent Cancer
3. Molecular Mechanism Of HIV Infecting The Healthy Cells Discovered.
4. Self-defense Mechanism of food borne bugs found
5. Specific Immune Mechanism against DNA viruses
6. A New Focus For The Mechanism Of Nerve Growth
7. Mechanism of Stem Cell Regulation Identified
8. Cancer-Killing Viruses Employ Multiple Mechanisms
9. Regulatory Mechanism for Tumor Suppressor Protein Identified
10. Study Identifies Mechanism Which May Help Tamoxifen Work Better
11. Genetic Mechanism Helps Explain Chronic Pain Disorders
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/17/2017)... ... February 17, 2017 , ... PrideStaff, a ... Rogers, was named to Staffing Industry Analysts' 2017 "Staffing 100 North America" list. ... have made notable contributions to the staffing industry over the last twelve months. ...
(Date:2/17/2017)... ... February 17, 2017 , ... Top neuroendocrine cancer doctors, nurses ... Foundation Summit from February 21 - 23 in Beaver Creek, CO. It was announced ... the Summit’s second year in Beaver Creek, hosting over 60 faculty members and addressing ...
(Date:2/16/2017)... ... February 17, 2017 , ... ... took over 10 years of research, development and clinical trials, the founder of ... is a patented compound of FDA approved ingredients that when infused into alcohol, ...
(Date:2/16/2017)... ... February 17, 2017 , ... ... financial planning services to families and entrepreneurs in the Birmingham area, is announcing ... mother who needs assistance with her medically challenged son, Anius. , Anius is ...
(Date:2/16/2017)... ... February 16, 2017 , ... PRESS RELEASE, FOR IMMEDIATE RELEASE:, ... David A Doege is excited to announce the launch of Doege Development, LLC, ... builds, design build, and site improvements. , Mr. Doege says, "I am so ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... AMSTERDAM , Feb. 17, ... connected health offerings at the  ...  (NYSE: PHG,AEX: PHIA), a global ... a broad range of population ... personal health solutions, fully integrated in a ...
(Date:2/17/2017)... Feb. 17, 2017  Noble Capital Markets announced today ... Inc. (Nasdaq: EPIX ). The report was ... Raja , PhD. ESSA Pharmaceuticals is a ... prostate cancer (CRPC). Its lead compound EPI-506, is a ... domain of the androgen receptor, thereby has potential to ...
(Date:2/16/2017)... MADISON, N.J. , Feb. 16, 2017 ... leading provider of diagnostic information services, today announced that ... Admired Companies" for 2017 by Fortune. ... only six companies in the "Health Care: Pharmacy and ... the only diagnostic information services company to attain the ...
Breaking Medicine Technology: